Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0034186 (pyelonephritis)
 6,144 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The authors present obtained data on the frequency of genotypes and A and C alleles of polymorphous gene related to Angiotension II first type receptor in patients of Poltava region. These patients were with chronic pyelonephritis and arterial hypertension. Therapeutic efficacy of candesartan treatment of the patients and at the same time their genotypes were considered. Obtained data evidence that AC genotype is more often found among patients with reniparenchymal hypertension, genotype CC is less found among these patients and genotype AA occupies an intermediate place (in 1,7 times less found than among healthy individuals and in 2,2 times more often than among patients with essential hypertension). Candesartan used in monotherapy has a high clinical efficiency in the treatment of patients with AC genotype. Patients with genotype AA and severe course of their disease have to be in a complex treatment or prescribed is applied candesartan in high dosage.
 ...
PMID:[Clinical efficiency of candesartan in patients with renoparenchymal hypertension in dependence on genotype of angeotensin II receptors of I type]. 1731 90

Now necessity of the strict control arterial pressure (AP) is conventional at chronic diseases of kidneys. Inhibitors of receptors AT1R (BAR) are recognized all over the world as preparations of the first of some for treatment of renoparenchimal hypertensia. The purpose research--to study of clinical effect of Candesartan at patients with renoparenchimal hypertensia depending on a genotype. Survey 50 patients with inspected patients with renoparenchimal hypertensia on a background of chronic pyelonephritis, polymorphism of gene of angiotensin 11 of the first type is certain. Patients appointed Kandesartan in doses of 8-32 (Mg), observed in current of 12 months. By results of research the genotype AA is revealed at 46%, AC at 48%, CC at 6% of patients. Allel A it is revealed in a genotype of 94%, allel C - 54% of patients of renoparenchimal hypertensia. A target level the AP will reach at 94.,3% patients. Kandesartan has shown high clinical effect at all variants of polymorphism of gene AT1R.
 ...
PMID:[Pharmacogenetic aspects of candesartan application for the treatment of arterial hypertension in patients with chronic pyelonephritis]. 2528 11